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Abstract
Introduction Epidemiologic studies have not shown a strong
relationship between blood levels of polychlorinated biphenyls
(PCBs) and breast cancer risk. However, two recent studies
showed a stronger association among postmenopausal white
women with the inducible M2 polymorphism in the cytochrome
P450 1A1 (CYP1A1) gene.
Methods In a population-based case-control study, we
evaluated breast cancer risk in relation to PCBs and the
CYP1A1 polymorphisms M1 (also known as CYP1A1*2A), M2
(CYP1A1*2C), M3 (CYP1A1*3), and M4 (CYP1A1*4). The
study population consisted of 612 patients (242 African
American, 370 white) and 599 controls (242 African American,
357 white).
Results There was no evidence of strong joint effects between
CYP1A1 M1-containing genotypes and total PCBs in African
American or white women. Statistically significant multiplicative
interactions were observed between CYP1A1 M2-containing
genotypes and elevated plasma total PCBs among white
women (P value for likelihood ratio test = 0.02). Multiplicative
interactions were also observed between CYP1A1  M3-
containing genotypes and elevated total PCBs among African
American women (P value for likelihood ratio test = 0.10).
Conclusions Our results confirm previous reports that CYP1A1
M2-containing genotypes modify the association between PCB
exposure and risk of breast cancer. We present additional
evidence suggesting that CYP1A1 M3-containing genotypes
modify the effects of PCB exposure among African American
women. Additional studies are warranted, and meta-analyses
combining results across studies will be needed to generate
more precise estimates of the joint effects of PCBs and
CYP1A1 genotypes.
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Introduction
The role of organochlorine compounds such as polychlorin-
ated biphenyls (PCBs) as etiologic agents for breast can-
cer has been investigated in several epidemiologic studies,
but findings are inconsistent [1]. Initial studies examining
breast tissue or serum showed significantly higher concen-
trations of PCBs in patients with breast cancer compared
with controls [2-6], but more recent studies observed no
association [7-10] or an inverse association [11] with
breast cancer.
Several mechanisms have been proposed to explain how
PCB exposure might increase the risk of breast cancer [12-
15]. Owing to their lipophilic nature, organochlorine com-
pounds undergo lifelong sequestration in animal and
human adipose tissues. Adipose tissue within the human
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breast contains measurable levels of PCBs [16]. Metabo-
lism of PCBs within breast tissue can generate reactive
intermediates that cause oxidative damage and react with
DNA. The proposed mechanism involves cytochrome P450
1A1 (CYP1A1), a gene that is inducible by PCBs [17,18].
CYP1A1 encodes aryl hydrocarbon hydrolase (AHH), an
enzyme involved in the production of reactive epoxide inter-
mediates from polycyclic aromatic hydrocarbons, steroid
hormones, and other aromatic compounds [19]. On the
basis of this model, individuals with higher CYP1A1 activity
would be at increased risk of breast cancer when exposed
to high levels of PCBs.
Several polymorphisms have been identified in CYP1A1,
some of which lead to more highly inducible AHH activity
[19-22]. CYP1A1 polymorphisms include M1 (T→C sub-
stitution at nucleotide 3801 in the 3'-noncoding region),
M2 (A→G substitution at nucleotide 2455 leading to an
amino acid change of isoleucine to valine at codon 462),
M3 (T→C substitution at nucleotide 3205 in the 3'-non-
coding region), and M4 (C→A substitution at nucleotide
2453 leading to an amino acid change of threonine to
asparagine at codon 461). Studies of CYP1A1 in cultured
human lymphocytes showed significantly elevated levels of
inducible enzyme activity among persons with M2 geno-
types [20,22]. Crofts and colleagues [21] reported that M2
alleles were associated with increased CYP1A1 inducibil-
ity at the mRNA level, and a threefold elevation in AHH
enzyme activity. The M1 allele also encodes an inducible
form of CYP1A1 [19,22,23].
Two recent epidemiologic studies showed an increased
risk of breast cancer among postmenopausal white women
with at least one M2 (valine) variant allele of CYP1A1 and
a high serum level of PCBs [24,25]. These findings sug-
gest that interactions between CYP1A1  polymorphisms
and PCBs could be involved in the development of breast
cancer, and genotyping for CYP1A1 could help to resolve
inconsistencies in past epidemiologic studies. We used
data from the Carolina Breast Cancer Study (CBCS), a
population-based case-control study of African American
and white women in North Carolina, to evaluate the effects
of PCBs and CYP1A1 genotypes in relation to breast can-
cer risk.
Materials and methods
Study population
CBCS study participants were women aged 20–74 years
residing in 24 contiguous counties in central and eastern
North Carolina [26]. Patients were women with a first diag-
nosis of invasive breast cancer identified through a rapid
ascertainment system implemented in cooperation with the
North Carolina Central Cancer registry. Controls were
selected from records of the North Carolina Division of
Motor Vehicles and US Health Care Financing Administra-
tion, and were frequency-matched to patients on the basis
of race and age. Information was collected through in-per-
son interviews and included reproductive history, diet and
lifestyle factors, a detailed family history of cancer, and
occupational history. About 98% of participants who were
interviewed agreed to give a 30 ml blood sample at the time
of interview. Informed consent to obtain DNA and measure-
ment of plasma concentration of PCBs was sought with the
use of a form approved by the Institutional Review Board of
the UNC School of Medicine in compliance with the Hel-
sinki Declaration.
The CBCS was conducted in two phases. Phase I of the
study was conducted between May 1993 and December
1996 [26]. Phase II of the study was conducted between
1996 and 2001. The total numbers of participants enrolled
in Phase I of the CBCS were 861 patients (335 African
American, 526 white) and 790 controls (332 African Amer-
ican and 526 white). The response rates were 76% for
patients and 55% for controls. Genotyping for CYP1A1
was performed on the first 688 breast cancer patients and
702 controls enrolled in Phase I of the CBCS. Laboratory
assays for organochlorines were conducted on blood sam-
ples from 748 patients and 659 controls in Phase I of the
CBCS [26]. The present analyses were based on Phase I
participants for whom both CYP1A1 genotyping and orga-
nochlorine measurements were available: 612 patients
(242 African American, 370 white) and 599 controls (242
African American, 357 white).
Laboratory methods
Methods for identification of plasma PCBs on CBCS
plasma samples using gas chromatography/electron cap-
ture detection have been described previously [26]. Meth-
ods for genotyping of CYP1A1 on CBCS samples using
restriction fragment length polymorphism–polymerase
chain reaction have been described previously [27]. In a
newly proposed nomenclature for CYP1A1 alleles, the M1
allele corresponds to CYP1A1*2A, M2 to CYP1A1*2C,
M3 to CYP1A1*3, and M4 to CYP1A1*4 [28]. Data were
missing on the following CYP1A1  genotypes due to
unreadable gels or failure to amplify: M1 (10 patients and 7
controls), M2 (none missing), M3 (10 patients and 7 con-
trols), and M4 (none missing). To correct for differences in
plasma concentrations of chlorinated hydrocarbons attrib-
utable to blood lipids, the quantity of different lipid compo-
nents in the plasma of each subject was measured with an
automated enzymic assay, as described previously [26].
Statistical methods
Imputed total PCB values were used in the data analyses.
Imputation was performed by setting zero values and val-
ues below the detection limit (0.0125 ng/ml) to the detec-
tion limit divided by the square root of 2 (26). Hornung and
Reed [29] recommended this method of imputation as anAvailable online http://breast-cancer-research.com/content/7/1/R12
R14
accurate approach for computing means and standard
deviations for variables that include nondetectable values.
In the present study, imputation did not affect the estima-
tion of odds ratios (ORs) for breast cancer and total PCBs,
because individuals in the lowest category (that is, below
the median) remained in the lowest category after imputa-
tion. Lipid-adjusted total PCBs levels were calculated with
Equation 2 of Phillips and colleagues [30]. Univariate anal-
yses were performed for total PCBs, lipid-adjusted total
PCBs, low to moderate chlorinated PCBs, highly chlorin-
ated PCBs, and individual PCB congeners 99, 105, 118,
and 153. Among controls in the CBCS, levels of individual
PCB congeners and congener groups were highly intercor-
related [31]. ORs for the joint effects of CYP1A1 geno-
types and PCB exposure did not differ substantially
according to specific PCB congeners or congener groups,
and ORs were similar to results obtained with total PCBs.
We did not observe differences in ORs for breast cancer
and PCB exposure, or the joint effects of CYP1A1 geno-
types and PCBs, when we analyzed PCB congeners 99,
105, 118, or 153 alone, as suggested by Demers and col-
leagues [32]. Therefore, only results for lipid-adjusted total
PCBs are presented.
Adjusted ORs for breast cancer and 95% confidence inter-
vals (CIs) were calculated from unconditional logistic
regression models. Total PCBs were categorized as
greater than or equal to versus below the median, on the
basis of the distribution in African American or white con-
trols separately. PROC GENMOD of software package
SAS (version 8.1; SAS Institute, Cary, NC) was used to
incorporate offsets derived from the sampling probabilities
used to identify eligible participants. Covariates included
age, race (whites/African Americans), parity (nulliparous, 1
or  ≥ 2), use of hormone replacement therapy (never or
ever), oral contraceptive use (never or ever), breast feeding
(never or ever), smoking (never, current, or former smoker),
alcohol consumption (yes/no), family history of breast can-
cer (yes/no), benign breast biopsy (yes/no), income (less
than $30,000/year or at least $30,000/year), and educa-
tion (lower than high school, or high school and above).
Continuous covariates, which included height, waist/hip
ratio, and body mass index, were categorized on the basis
of the median values of each variable in all controls.
ORs did not differ after adjusting for additional covariates,
so results are presented for African American and white
women adjusting for sampling fractions and age. Menopau-
sal status was defined as described previously [27] and
used to stratify analyses of CYP1A1 genotypes and PCB
levels. Stratified analyses were also conducted on the
basis of smoking history (ever or never). In addition, we esti-
mated the increase in odds of breast cancer per 0.10 ng/
ml increase in total PCB levels by coding lipid-adjusted
total PCBs as a continuous variable, and stratifying on
CYP1A1 genotypes. Linearity in the logit was tested using
the Box–Tidwell transformation test as implemented in
SAS (version 8.1). The assumption of linearity was not vio-
lated in premenopausal or postmenopausal African Ameri-
can or white women.
To assess the interaction on the additive scale between
PCB levels and CYP1A1  genotypes, indicator variables
were created for each category of joint exposure of PCBs
and  CYP1A1  genotype. Women with the homozygous
common (non-M1, non-M2, non-M3, or non-M4) genotypes
and the lowest level of exposure to PCBs were used as a
common reference group. Interaction contrast ratios (ICRs)
and 95% CIs were calculated for joint effects of the M1
genotype and PCBs [33]. ICR values greater than zero indi-
cate greater than additive effects (synergy), and 95% CIs
for the ICR that exclude zero can be used as a test for sta-
tistical significance at an alpha level of 0.05. To test for
interaction on a multiplicative scale, likelihood ratio tests
(LRTs) were conducted comparing logistic regression
models with main effect terms for lipid-adjusted total PCBs
and CYP1A1 genotypes and a product interaction term
compared with models with main effects only. P values for
LRTs less than 0.20 were considered statistically signifi-
cant [34].
To test for independence of environmental exposure and
genotype, means, medians, and distributions of total PCBs
were determined in relation to CYP1A1 genotypes among
African American and white controls. Medians for lipid-
adjusted total PCBs were compared by using the Wilcoxon
rank sum test. There were no statistically significant differ-
ences in medians for total PCBs comparing participants
with  CYP1A1  M1-containing versus non-M1-containing
genotypes, M2 versus non-M2, M3 versus non-M3, or M4
versus non-M4 genotypes.
Results
Genotype frequencies for CYP1A1, and ORs for breast
cancer, have previously been reported for the CBCS [27].
In brief, genotype frequencies for CYP1A1 M1- and M3-
containing genotypes were higher among African Ameri-
cans than among whites, whereas M2- and M4-containing
genotypes were more prevalent among whites. ORs for
CYP1A1 genotypes and breast cancer were close to the
null in African Americans and whites [27]. The association
between plasma levels of total PCBs and breast cancer in
the CBCS was reported previously [26]. A weak positive
association for high levels of PCBs and breast cancer was
found among African American women. ORs were close to
the null for PCBs and breast cancer in white women.
ORs for breast cancer estimating the joint effects of total
PCBs and CYP1A1 M1 genotypes on an additive scale are
presented in Table 1. ORs were slightly elevated for PCBBreast Cancer Research    Vol 7 No 1    Li et al.
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exposure greater than or equal to the median among pre-
menopausal African American women regardless of
CYP1A1 M1 genotype. There was no evidence for strong
joint effects of PCBs and CYP1A1 M1-containing geno-
types. ICRs were close to zero in African American and
white women, and LRTs were not statistically significant.
Joint effects for PCBs and CYP1A1 M2-containing geno-
types among white women are presented in Table 2.
Greater than additive joint effects were observed among all
participants, with an ICR greater than zero and an associ-
ated  P  value of 0.03. Although imprecise, joint effects
seemed to be stronger among premenopausal than among
postmenopausal women. P  values for LRTs were 0.02
among all participants, 0.007 among premenopausal
women, and 0.66 among postmenopausal women.
ORs estimating the joint effects of PCBs and CYP1A1 M3
genotype among African American women are presented in
Table 3. ORs were slightly elevated for women with ele-
vated PCB levels and CYP1A1 M3-containing genotypes.
An ICR greater than zero was observed in postmenopausal
women. P values for LRTs were 0.10 in all participants,
0.71 among premenopausal women, and 0.11 in postmen-
opausal women. Joint effects of PCBs and CYP1A1 M4
genotypes among white women are presented in Table 4.
An ICR greater than zero (P = 0.03) was observed among
Table 1
Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M1 genotypes in African American and white women
Total PCBsa CYP1A1 M1 
genotype
All participants Premenopausal Postmenopausal
Patients/
controls
OR (95% CI)b Patients/
controls
OR (95% CI)b Patients/
controls
OR (95% CI)b
African 
Americans
<0.430 Non-M1 66/75 Referent 46/51 Referent 20/24 Referent
≥0.430 Non-M1 75/67 1.5 (0.9–2.5) 21/16 1.9 (0.9–4.2) 54/51 1.0 (0.5–2.3)
<0.430 Any M1 42/46 1.0 (0.6–1.7) 35/33 1.2 (0.6–2.2) 7/13 0.6 (0.2–1.8)
≥0.430 Any M1 59/54 1.4 (0.8–2.5) 17/14 1.7 (0.8–4.1) 42/40 1.0 (0.5–2.3)
ICR (95% CI) 0.0 (-0.9,0.9) -0.3 (-2.2,1.6) 0.4 (-0.5,1.3)
Whites
<0.349 Non-M1 174/133 Referent 118/83 Referent 56/50 Referent
≥0.349 Non-M1 122 148 0.7 (0.5–1.0) 38/43 0.6 (0.4–1.1) 84/105 0.8 (0.5–1.3)
<0.349 Any M1 45/44 0.8 (0.5–1.2) 29/31 0.7 (0.4–1.2) 16/13 1.1 (0.5–2.5)
≥0.349 Any M1 29/32 0.8 (0.4–1.4) 11/10 0.7 (0.3–1.9) 18/22 0.8 (0.4–1.7)
ICR (95% CI) 0.4 (-0.2,0.9) 0.5 (-0.3,1.2) 0.0 (-1.1,1.0)
aLipid-adjusted total imputed PCBs (ng/ml).
bOdds ratios adjusted for age and sampling fractions.
Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.
Table 2
Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M2 genotypes in white women
Total PCBsa CYP1A1 M2 genotype All participants Premenopausal Postmenopausal
Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b
<0.349 Non-M2 210/158 Referent 141/98 Referent 69/60 Referent
≥0.349 Non-M2 138/166 0.7 (0.5–1.0) 45/51 0.6 (0.4–1.0) 93/115 0.8 (0.5–1.2)
<0.349 Any M2 11/20 0.4 (0.2–0.8) 8/16 0.3 (0.1–0.8) 3/4 0.7 (0.1–3.1)
≥0.349 Any M2 15/14 0.9 (0.4–1.9) 6/2 2.1 (0.4–10.6) 9/12 0.7 (0.3–1.9)
ICR (95% CI) 0.8 (0.1, 1.6) 2.1 (-1.3,5.5) 0.3 (-0.9,1.5)
aLipid-adjusted total imputed PCBs (ng/ml).
bOdds ratios adjusted for age and sampling fractions.
Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.Available online http://breast-cancer-research.com/content/7/1/R12
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postmenopausal women. The P value for the LRT in post-
menopausal women was 0.07. ICRs greater than zero for
the joint effects of exposures with ORs less than 1.0 can be
interpreted as antagonism [33]. Results were similar
among smokers and non-smokers (data not shown).
ORs for breast cancer per 0.10 ng/ml increase in lipid-
adjusted total PCBs showed only slight differences
according to CYP1A1 M2 genotypes in white women. ORs
for premenopausal women were 1.3 (95% CI 0.7–2.3) for
those with CYP1A1  M2-containing genotypes and 1.0
(95% CI 0.9–1.1) for non-M2 genotypes. The correspond-
ing ORs for postmenopausal women were 1.2 (95% CI
0.8–1.8) and 1.1 (1.0–1.2).
Discussion
We estimated the joint effects of plasma levels of total
PCBs and CYP1A1 genotypes in association with breast
cancer, using previously collected data from a population-
based case-control study of African American and white
women in North Carolina. ORs were slightly elevated for
premenopausal white women with CYP1A1 M2-containing
genotypes and lipid-adjusted total PCBs greater than the
median, and for postmenopausal African American women
with M3-containing genotypes and total PCBs greater than
the median. ORs and ICRs were imprecise because of
small sample size, and many of our results could be due to
chance. However, biologic evidence and previous epidemi-
ologic studies support the possibility of causal interaction
between CYP1A1 genotypes (in particular, M2-containing
genotypes) and PCB exposure in the etiology of breast
cancer.
PCBs are metabolized by cytochrome P450 enzymes, acti-
vate CYP1A1, and produce free-radical-induced oxidative
DNA damage in breast tissue [35]. With regard to
CYP1A1 M1-containing genotypes, a previous study by
Laden and colleagues [25] did not report a positive associ-
ation for M1-containing genotypes and high levels of PCBs
in postmenopausal women: the OR for women in the
highest one-third of lipid-adjusted total PCBs (at least 0.67
µg per g lipid) and M1-containing genotypes was 1.1 (95%
CI 0.5–2.5) compared with women in the lowest one-third
of PCBs with non-M1-containing genotypes. In our data
set, the corresponding age-adjusted OR for lipid-adjusted
total PCBs of 0.67 ng/ml or more and CYP1A1 M1-con-
taining genotypes among postmenopausal white women
was 1.8 (95% CI 0.5–6.9).
Table 3
Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M3 genotypes in African American women
Total PCBsa CYP1A1 M3 genotype All participants Premenopausal Postmenopausal
Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b
<0.430 Non-M3 95/95 Referent 73/70 Referent 22/25 Referent
≥0.430 Non-M3 105/100 1.3 (0.8–2.0) 31/24 1.6 (0.8–3.2) 74/76 1.0 (0.5–2.0)
<0.430 Any M3 13/26 0.6 (0.3–1.2) 8/14 0.7 (0.3–1.7) 5/12 0.5 (0.2–1.6)
≥0.430 Any M3 29/21 1.6 (0.8–3.2) 7/6 1.5 (0.5–4.7) 22/15 1.5 (0.6–3.6)
ICR (95% CI) 0.8 (-0.3,1.9) 0.2 (-1.7,2.1) 1.0 (-0.2,2.1)
aLipid-adjusted total imputed PCBs (ng/ml).
bOdds ratios adjusted for age and sampling fractions.
Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.
Table 4
Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M4 genotypes in white women
Total PCBsa CYP1A1 M4 genotype All participants Premenopausal Postmenopausal
Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b Patients/controls OR (95% CI)b
<0.349 Non-M4 202/159 Referent 132/103 Referent 70/56 Referent
≥0.349 Non-M4 139/163 0.7 (0.5–1.0) 46/48 0.8 (0.5–1.2) 93/115 0.7 (0.4–1.1)
<0.349 Any M4 19/19 0.8 (0.4–1.6) 17/11 1.2 (0.5–2.7) 2/8 0.2 (0.0–0.9)
≥0.349 Any M4 14/17 0.7 (0.3–1.6) 5/5 0.8 (0.2–2.9) 9/12 0.7 (0.3–1.7)
ICR (95% CI) 0.2 (-0.6,1.0) -0.1 (-1.6,1.3) 0.8 (0.1,1.5)
aLipid-adjusted total imputed PCBs (ng/ml).
bOdds ratios adjusted for age and sampling fractions.
Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.Breast Cancer Research    Vol 7 No 1    Li et al.
R17
With regard to CYP1A1 M2-containing genotypes, Moys-
ich and colleagues [24] reported an OR for breast cancer
of 2.9 (95% CI 1.2–7.5) in postmenopausal women with
total PCBs between 3.72 and 19.04 ng/g and CYP1A1
M2-containing genotypes compared with women with low
PCBs and non-M2-containing genotypes. In our data set,
the corresponding age-adjusted OR for total PCBs of 3.73
ng/ml or more (not lipid-adjusted) and CYP1A1 M2-con-
taining genotypes was 6.3 (95% CI 0.7–55.0). Laden and
colleagues [25] reported an OR of 2.8 (95% CI 1.0–7.8)
for women with the highest one-third of lipid-adjusted total
PCBs (0.67 µg per g lipid) and CYP1A1 M2-containing
genotypes, compared with women in the lowest one-third
of PCBs and non-M2-containing genotypes. The corre-
sponding OR in our data set for lipid-adjusted total PCBs
≥ 0.67 ng/ml and CYP1A1 M2-containing genotypes was
4.7 (95% CI 0.5–43.1). It would be helpful to combine indi-
vidual-level results across these three studies to obtain
more precise estimates of the joint effects of CYP1A1 gen-
otypes and high levels of PCB exposure.
A strength of our study is the fact that we included both
African American and white women, and we examined the
effects of the four known CYP1A1 alleles: M1, M2, M3, and
M4. Previous studies [24,25] included only white women
and did not estimate ORs for CYP1A1 M3- or M4-contain-
ing genotypes. In previous analyses of this data set [26],
African American women showed higher plasma levels of
PCBs and a stronger relationship between total PCBs and
breast cancer than that in white women. Our results sug-
gest that further study of CYP1A1 M3-containing geno-
types in African American women is warranted, particularly
in combination with PCB exposure. Another strength of our
study is that fact that we estimated joint effects for specific
PCB congener groups and CYP1A1 genotypes. PCB con-
gener groups may differ in biologic activity in ways that are
relevant to breast cancer etiology [35-39]. However,
because of the strong intercorrelation of specific conge-
ners with total PCBs, we were unable to distinguish strong
congener-specific effects.
A weakness of our study was the fact that, because of the
small sample size, we were unable to estimate ORs with
precision in all of the subgroups of interest. Moysich and
colleagues [24] reported that breast cancer risk was signif-
icantly increased among women with elevated PCB body
burden and CYP1A1 M2 genotypes who had ever smoked
cigarettes. Laden and colleagues [25] observed similar
results. We did not observe differences in ORs for the joint
effects of total PCBs and CYP1A1 genotypes according to
smoking status. However, we lacked power to address the
effects of smoking dose or duration. ORs were imprecise
when we subdivided study participants on the basis of
menopausal status, and any differences could be due to
chance. Owing to the case-control study design, patients
were enrolled after diagnosis of breast cancer. As
described previously [26], we did not observe evidence for
disease-related changes in plasma organochlorine levels
when we adjusted for weight loss or gain and stage at diag-
nosis. Limited information on diet was collected in this
study. We did not observe correlations between total PCB
levels and the consumption of fruits, vegetables, or fish
(data not shown), but the confounding effects of other die-
tary exposures cannot be ruled out.
Conclusions
Data from the CBCS provides evidence that subgroups of
women with CYP1A1 M2 and M3 polymorphisms and high
levels of PCB exposure might have a modestly elevated risk
of breast cancer. Our results confirm findings from previous
studies with respect to the highly inducible CYP1A1 M2
genotype, and suggest that M3-containing genotypes
might also modify risk of breast cancer associated with
PCB exposure in African American women. Additional
studies with a large sample size are warranted to confirm or
refute these findings. In addition, meta-analyses combining
individual-level data from epidemiologic studies of
CYP1A1 and breast cancer will be needed to generate
more precise estimates of the joint effects of PCBs and
CYP1A1 genotypes.
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